




RealRate

PHARMACEUTICAL 2016

Biomarin Pharmaceutical INC
Rank 132 of 295

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 302%, being 39% points above the market average of 263%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	1,089,639	Assets	3,729,368
Cost of Goods Sold	152,008	Liabilities	1,328,521
Intangible Assets	881,035	Expenses	1,056,079
Liabilities, Current	445,457	Revenues	889,895
Liabilities, Non-Current	44,588	Stockholders Equity	2,400,847
Other Assets	1,054,487	Net Income	-171,799
Other Compr. Net Income	-6,433	Comprehensive Net Income	-175,016
Other Expenses	-133,006	BaseVar	3,507,956
Other Liabilities	838,476	ECR before LimitedLiability	200%
Other Net Income	-5,615	Economic Capital Ratio	302%
Other Revenues	889,895		
Property and Equipment	704,207		
Research and Development	634,806		
Selling, General and Administrative Expense	402,271		